The South Korean Computed Tomography (CT) market, a segment within the global $226.64 million market exhibiting a 6.33% CAGR, presents a compelling investment opportunity. While precise South Korean market figures for 2019-2024 are unavailable, extrapolating from the global CAGR and considering South Korea's advanced healthcare infrastructure and high technological adoption rate, we can project significant growth. The market is driven by factors such as the rising prevalence of chronic diseases (cardiovascular, cancer, neurological disorders), an aging population increasing the demand for diagnostic imaging, and government initiatives promoting advanced medical technology. Furthermore, the presence of major international players like GE Healthcare, Siemens Healthineers, and Philips, alongside domestic players, fosters competition and innovation, leading to technological advancements in CT scanner capabilities (e.g., faster scan times, improved image resolution, reduced radiation exposure). Market segmentation reveals a likely strong demand across applications (oncology, cardiology, neurology dominating) and end-users (hospitals and diagnostic centers). The high cost of CT scanners and associated maintenance, coupled with stringent regulatory requirements, could act as market restraints. However, the ongoing technological advancements in CT technology and increasing government support for healthcare infrastructure upgrades are expected to offset these limitations, resulting in sustained market expansion in South Korea. Looking ahead to 2025-2033, the South Korean CT market is projected to experience robust growth. The country's well-developed healthcare system, coupled with its emphasis on preventive healthcare and early diagnosis, will contribute significantly to this expansion. Continued technological innovation, the introduction of advanced CT scanning techniques, and rising affordability will broaden market access. Specifically, advancements in low-dose CT scanning, enabling earlier and safer detection of various diseases, will be a key driver. The competitive landscape will likely remain dynamic, with both international and domestic players vying for market share through technological innovation, strategic partnerships, and product differentiation. Understanding the nuances of the regulatory environment and adapting to the evolving needs of healthcare providers will be crucial for sustained success in this market. Recent developments include: In March 2022, Philips Korea unveiled Greeting CT Premium at 37th Korea International Medical & Hospital Equipment Show (KIMES2022) held at Samsung-dong COEX in Seoul., In January 2022, Bayer AG's MEDRAD Centargo, a computed tomography device received approval from South Korea's Ministry of Food and Drug Safety.. Key drivers for this market are: Increasing Prevalence of Chronic Diseases, Rising Geriatric Population; Increasing Technological Advancements. Potential restraints include: Increasing Prevalence of Chronic Diseases, Rising Geriatric Population; Increasing Technological Advancements. Notable trends are: Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

176.579 (number) in 2019. According to U.S. Office of Management and Budget (OMB), “Asian” refers to a person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent, including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. The Asian population includes people who indicated their race(s) as “Asian” or reported entries such as “Asian Indian,” “Chinese,” “Filipino,” “Korean,” “Japanes"".

BackgroundThe main pulmonary artery diameter (mPA), aortic diameter (Ao), and the mPA/Ao ratio, easily measured using chest computed tomography (CT), provide information that enables the diagnosis and evaluation of cardiopulmonary diseases. Here, we used CT to determine the sex- and age-specific distribution of normal reference values for mPA, Ao, and mPA/Ao ratio in an adult Korean population.MethodsData from non-contrast, ECG-gated, coronary-calcium-scoring CT images of 2,547 individuals who visited the Health Screening Center of the Severance Hospital were analyzed. Healthy individuals (n = 813) included those who do not have hypertension, diabetes, asthma, obstructive lung disease, ischemic heart disease, stroke, smoking, obesity, and abnormal CT findings. Both mPA and Ao were measured at the level of bifurcation of the main pulmonary artery.ResultsThe mean mPA and Ao were 25.9 mm and 30.0 mm in healthy participants, respectively, while the mean mPA/Ao ratio was 0.87. Medical conditions associated with a larger mPA were male, obesity, smoking history, hypertension, and diabetes. A larger mPA/Ao ratio was associated with female, the obese, non-smoker, normotensive, and normal serum level of lipids, while a smaller mPA/Ao ratio was associated with older age. In healthy individuals, the 90th percentile sex-specific mPA, Ao, and mPA/Ao ratio were, 31.3 mm (95% CI 29.9–32.2), 36.8 mm (95% CI 35.7–37.5), and 1.05 (95% CI 0.99–1.07) in males, and 29.6 mm (95% CI 29.1–30.2), 34.5 mm (95% CI 34.1–34.9), and 1.03 (95% CI 1.02–1.06) in females, respectively.ConclusionIn the Korean population, the mean mPA reference values in male and female were 26.5 mm and 25.8 mm, respectively, while the mean mPA/Ao ratio was 0.87. These values were influenced by a variety of underlying medical conditions.

The size of the Computed Tomography Market in South Korea market was valued at USD 226.64 Million in 2023 and is projected to reach USD 348.28 Million by 2032, with an expected CAGR of 6.33% during the forecast period. The South Korea computed tomography market is growing at a very brisk pace due to technology and a growing demand for diagnostic imaging in the healthcare sector. South Korea has very high-quality healthcare infrastructure and strong emphasis on early detection of diseases and preventive care especially related to chronic diseases such as cancer, cardiovascular conditions, and respiratory disorders. It is through such emphasis on accurate diagnosis that CT scan proves to be significant in modern medical practices. Market growth factors are therefore immense since more investments are being made in health technology, and hospitals and diagnostic centers are introducing more sophisticated CTs to their systems in the form of multi-slice and high-resolution scanners. Not only do they improve the image quality but also reduce the radiation dose to be as low as possible and within safe standards for patients. Continuing the trend, the increasing elderly population in South Korea along with lifestyle-related diseases sparks the need for highly advanced imaging solutions. Artificial intelligence and machine learning in the imaging process are also changing the market to improve diagnostic accuracy as well as efficiency in the operation. Major constraints that are facing the CT market in South Korea include high prices for high-end CT equipment and a requirement for constant education of staff. On the other hand, renewed interest in health care provision and access by the South Korean government is most probably going to fuel further growth in the CT market, as it signals improved healthcare services that are more modern in the region. Recent developments include: In March 2022, Philips Korea unveiled Greeting CT Premium at 37th Korea International Medical & Hospital Equipment Show (KIMES2022) held at Samsung-dong COEX in Seoul., In January 2022, Bayer AG's MEDRAD Centargo, a computed tomography device received approval from South Korea's Ministry of Food and Drug Safety.. Key drivers for this market are: Increasing Prevalence of Chronic Diseases, Rising Geriatric Population; Increasing Technological Advancements. Potential restraints include: Lack Of Proper Reimbursement And Stringent Regulatory Approval Procedures, High Cost of Equipment. Notable trends are: Oncology Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

The South Korean diagnostic imaging equipment market exhibits robust growth, driven by factors such as a rising geriatric population necessitating increased screening and diagnosis, growing prevalence of chronic diseases like cancer and cardiovascular ailments, and rising healthcare expenditure. Technological advancements, including the development of AI-powered image analysis tools and minimally invasive procedures, further fuel market expansion. The market is segmented by product type (X-ray, Ultrasound, MRI, CT, Nuclear Medicine, Fluoroscopy, Mammography), application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology), and end-user (Hospitals, Diagnostic Centers). While the precise market size for 2025 is not provided, based on a reported CAGR of 5.20% and considering typical market dynamics in developed economies, we can reasonably estimate the market size to be between $500 million and $700 million USD in 2025. This estimate accounts for the projected increase from the previous year and the inherent variability within market growth projections. The forecast period of 2025-2033 suggests continued growth momentum, primarily driven by the aforementioned factors. However, potential restraints may include high equipment costs, regulatory hurdles for new technology adoption, and limited reimbursement policies that could impact market expansion rate. The competitive landscape is characterized by the presence of both global giants like GE Healthcare, Siemens Healthineers, and Philips, along with other significant players like Canon and Fujifilm. These companies are engaged in intense competition, focusing on technological innovation, strategic partnerships, and expansion of their service offerings. The market is projected to experience substantial growth in the coming years due to increasing demand for sophisticated diagnostic imaging techniques, improvements in healthcare infrastructure, and government initiatives to promote healthcare quality and access in South Korea. The shift toward advanced imaging technologies and the increasing integration of AI will also shape the market’s future trajectory. Within the segments, MRI and CT scanners are likely to witness higher growth rates due to their superior diagnostic capabilities compared to traditional methods. Recent developments include: In March 2021, Alpinion Medical Systems Co., Ltd, South Korea based company announced the launch of X-CUBE 90, a high-performance ultrasound diagnostic system., In January 2021, Israel-based Medic Vision announces that it has received clearance from the Korean Ministry of Food and Drug Safety administration (KFDA) and signed a partnership agreement with Nuclear Light Industry (NLI) ltd for selling iQMR in Korea. NLI ltd. will be operating as a licensed distributor of Medic Vision's iQMR, an image enhancement solution allowing fast MRI scans and enhanced image quality for increased MRI productivity, fewer repeating scans, and improved patients' experience.. Key drivers for this market are: Increasing Prevalence of Chronic Diseases and Rising Geriatric Population, Technological Advancements and Rapid Innovation. Potential restraints include: Increasing Prevalence of Chronic Diseases and Rising Geriatric Population, Technological Advancements and Rapid Innovation. Notable trends are: Magnetic Resonance Imaging (MRI) Segment is Expected to Account for the Largest Market Share.

mPA, Ao and mPA/Ao according to age in healthy reference group (n = 813).

Multivariate linear analysis for the effects of clinical characteristics on mPA, Ao, and mPA/Ao ratio.

aAdjusted odds ratio on the basis of risk factors, such as age, gender, hypertension, diabetes mellitus.bFalse positive discovery rate (FDR)-adjusted P-value.The combination of the polymorphisms of microRNA machinery genes in CRC patients and controls: male subgroup.

aAdjusted odds ratio on the basis of risk factors, such as age, gender, hypertension, diabetes mellitus. MDR, multifactor dimensional reduction.bFalse positive discovery rate (FDR)-adjusted P-value.The combination of miRNA machinery genes polymorphisms based on MDR and CRC patients.

CRC, colorectal cancer; SD, standard deviation; TNM, tumor node metastasis.*P-values were calculated using chi-squared tests for categorical data and two–side t-tests for continuous data.Baseline characteristics of colorectal cancer patients and control subjects.